Erschienen in:
03.04.2019 | Concise Research Reports
Savings from the EpiPen Authorized Generic: a Retrospective Analysis of Medicaid Data
verfasst von:
Inmaculada Hernandez, PharmD, PhD, William H. Shrank, MD, MSHS, Chester B. Good, MD, MPH, Walid F. Gellad, MD, MPH
Erschienen in:
Journal of General Internal Medicine
|
Ausgabe 9/2019
Einloggen, um Zugang zu erhalten
Excerpt
Authorized generics—generic drugs that are simply relabeled versions of the original brand-name drug—are a mechanism by which manufacturers can voluntarily lower drug prices. Although evidence from the early 2000s suggests that authorized generics lower prices in the presence of other independent generics,
1 the impact of authorized generics in markets with limited competition remains unknown. …